Previous close | 5.09 |
Open | 5.29 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 5.18 - 5.36 |
52-week range | 3.30 - 6.88 |
Volume | |
Avg. volume | 3,266 |
Market cap | 2.751M |
Beta (5Y monthly) | 0.71 |
PE ratio (TTM) | 0.16 |
EPS (TTM) | 0.32 |
Earnings date | 25 Jul 2024 - 29 Jul 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the results from its second Phase III study of tradipitant in motion sickness, confirming the previously reported results of two efficacy studies demonstrating that tradipitant is effective in the prevention of vomiting associated with motion sickness. This Phase III study was conducted in real-world conditions on boats in the coastal waters of the United States (U.S.).
Challenges and Strategic Developments Shape the Quarter
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q1 2024 Earnings Call Transcript May 8, 2024 Vanda Pharmaceuticals Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank you for standing by. My name is Hermine, and I will be your conference operator today. […]